Aptamers as Remarkable Diagnostic and Therapeutic Agents in Cancer Treatment
Nucleic acid aptamers are molecules that are being used in a large number of biomedical applications. Aptamers have the properties to bind to a wide range of molecules with high specificity and affinity for their target. These properties together with their small size and their ease of synthesis make them very attractive and promising for targeting diseases and therapeutic applications. Aptamers can serve as cancer diagnostic tools by detecting specific biomarkers, circulating cancer cells or imaging diseased tissue. On the other hand, aptamers can be used as therapeutic agents due to their potential antagonist activity, or as targeting agents. Therefore, they can be designed to deliver antitumor molecules such as chemotherapeutic drugs, siRNA or photodynamic therapy sensitizers to diseased tissues. Attempts are also made to synthesize aptamers-targeted nanoplatforms capable to ferry cargo and load onto them both imaging and therapeutic functions creating so called nanotheragnostics agents. In the future, its seems likely that aptamers will play an important role in diagnosis and treatment of several pathologies including cancer.
No Supplementary Data
No Article Media
Document Type: Research Article
Publication date: October 1, 2012
More about this publication?
- Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism and disposition. The journal serves as an international forum for the publication of timely reviews in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments. The journal covers the following areas:
In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; recent developments for the identification of drug metabolites and adducts.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites